Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulmonary Suffusion in Resectable or Ablatable Sarcoma or Colorectal Pulmonary Metastases
NCT03965234Phase 2Recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jul 2020
- Primary completion
- May 2029
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cisplatin micelle injection (HA132) in sarcoma and colorectal cancer (CRC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Incidence of local toxicities up to 2 years, Recommended phase II dose up to 5 years and 2 more. Started Jul 2020; status: recruiting.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
sarcomacolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03965234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03965234.